Follow-On Biologics: Defeat For Waxman, Win For Health Reform
This article was originally published in The Pink Sheet Daily
Executive Summary
Lopsided committee vote suggests that lengthy exclusivity is here to stay, which means that big pharma can get more comfortably behind the broader reform effort.
You may also be interested in...
Rep. Pallone’s Energy And Commerce Win Is Salve For Generics
Anna Eshoo, who championed the brand-friendly biosimilars pathway, had challenged Pallone for ranking member post in House Energy and Commerce Committee.
Waxman’s Congressional Exclusivity Set To Expire, But There Will Be No Equivalents
Retiring after 40 years in Congress, Waxman leaves an enormous legacy, but also many recent legislative defeats.
How "Clean" Will PDFUA V Be? Rep. Pitts Explains His Vacuuming Technique
Pennsylvania Republican Joe Pitts, chairman of the House Energy and Commerce Health Subcommittee, has a straightforward approach to reauthorizing the Prescription Drug User Fee Act – get it done early.